Today: 7 February 2026
Subscribe
Browse Category

Earnings Reports News 10 January 2026

Lam Research stock jumps on Mizuho target hike as chip-tool rally sets up next earnings test

Lam Research stock jumps on Mizuho target hike as chip-tool rally sets up next earnings test

Lam Research shares surged 8.7% to $218.36 Friday after Mizuho raised its price target and the PHLX chip index hit a record. Heavy trading snapped a two-day slide for Lam, which will report earnings Jan. 28. Applied Materials and KLA also posted strong gains. Traders are watching next week’s U.S. inflation data and the Fed’s policy meeting for signals on rate cuts.
10 January 2026
··
GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

AnaptysBio filed a motion to dismiss part of GSK’s claim in a Delaware court dispute over royalties from cancer drug Jemperli. The court is expected to hear the motion by early March, with trial set for July. GSK ADRs closed up 0.3% at $50.39 in New York; London shares slipped 0.26% to 1,886 pence. Investors await GSK’s Jan. 13 conference appearance and Feb. 4 results.
10 January 2026
····
Keppel Ltd stock: Feb. 5 results date is set — here’s what traders watch next

Keppel Ltd stock: Feb. 5 results date is set — here’s what traders watch next

Keppel Ltd will release its second-half and full-year 2025 results on Feb. 5, after three Keppel-sponsored REITs report from Jan. 30. Keppel shares closed Friday down 0.7% at S$10.47, trading near a 52-week high. About 2.06 million shares changed hands, with S$10.46 as support and S$10.56 as resistance. All financial releases will be made before market open, the company said.
10 January 2026
··
South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results

South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results

South32 shares closed up 1.1% at A$3.85, just below their 2026 high, after the miner released its 2026 calendar and set Feb. 12 for half-year results. The company confirmed a March 5 ex-dividend date and flagged a $60 million cost for the Mozal smelter shutdown in Mozambique. The S&P/ASX 200 slipped 0.03% as Rio Tinto fell 6.2%. Glencore shares surged over 10% on takeover talks with Rio Tinto.
10 January 2026
···
Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson reached a deal with the Trump administration to cut U.S. drug prices and won exemptions from tariffs on its pharmaceuticals. The company will sell medicines at discounted rates through TrumpRx.gov and announced two new U.S. manufacturing sites. J&J stock closed down 0.7% at $204.39. Terms of the agreement remain confidential.
10 January 2026
····
P&G stock in focus after Crest toothpaste label change — what to watch before Jan. 22 earnings

P&G stock in focus after Crest toothpaste label change — what to watch before Jan. 22 earnings

Procter & Gamble will change Kid’s Crest toothpaste packaging after Texas officials said label artwork encouraged unsafe fluoride use by children. The rollout began Jan. 1 and must last five years. P&G shares closed up 0.24% at $141.87, then slipped 0.17% after hours. Investors await the Jan. 22 earnings call for updates on volumes, pricing, and regulatory scrutiny.
10 January 2026
··
1 … 100 101 102 103 104 … 202

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
Go toTop